Anavex Life Sciences Income Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Selling, General & Admin	14.59	13.82	11.04	12.05	13.07	9.02
Research & Development	30.76	37.59	41.84	43.72	37.92	32.98
Total Operating Expenses	45.35	51.41	52.88	55.76	50.99	42
Operating Income	-38.57	-51.41	-52.88	-55.76	-50.99	-42
Interest Income	4.44	5.36	9.69	9.26	4.27	4.63
Interest Expense	-	-	-	-0.96	-	-
Other Non-Operating Income (Expense)	2.32	-0.33	0.19	-0.04	-0.9	-0.27
Total Non-Operating Income (Expense)	6.76	5.03	9.88	8.26	3.37	4.36
Pretax Income	-11	-46.38	-43	-47.51	-47.62	-37.64
Provision for Income Taxes	0.04	-	-	-	-	-
Net Income	-11.02	-46.38	-43	-47.51	-47.62	-37.64
Net Income to Common	-11.02	-46.38	-43	-47.51	-47.62	-37.64
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	88	85	83	80	77	70
Shares Outstanding (Diluted)	88	85	83	80	77	70
Shares Change	4.06%	2.18%	4.61%	3.74%	10.18%	19.95%
EPS (Basic)	-0.39	-0.54	-0.52	-0.60	-0.62	-0.54
EPS (Diluted)	-0.39	-0.54	-0.52	-0.60	-0.62	-0.54
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Free Cash Flow	-	-39.04	-30.81	-27.79	-24.24	-30.38
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-	-0.46	-0.37	-0.35	-0.32	-0.44
EBITDA	-38.57	-51.41	-52.88	-55.76	-50.99	-42
EBIT	-38.57	-51.41	-52.88	-55.76	-50.99	-42
Effective Tax Rate	-0.33%	0.00%	0.00%	0.00%	0.00%	0.00%

SEC Filings: 10-K · 10-Q